A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer.
Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer. PV-10 is a solution developed from Rose Bengal, a water-soluble dye commonly used to stain damaged cells in the eye. Early clinical trials show PV-10 can boost immune response in melanoma tumors, as well as the blood stream.
“Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said Shari Pilon-Thomas, Ph.D., assistant member of Moffitt’sImmunology Program.
In the initial study, researchers injected a single dose of PV-10 into mice with melanoma. The result was a significant reduction in the skin cancer lesions, as well as a sizable reduction in melanoma tumors that had spread to the lungs. The researchers said the dye solution appeared to produce a robust anti-tumor immune response and may be safer than existing immunological agents.
“We are currently in the middle of our first human clinical trial of PV-10 for advanced melanoma patients. In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection,” explained Amod A. Sarnaik, M.D., assistant member of Moffitt’s Cutaneous Oncology Program.
The Latest on: Melanoma
- Non-Melanoma Skin Cancer Treatment Market: Segment Snapshot and Table of Content (2017-2025) on December 15, 2017 at 7:08 am
New York, NY -- (SBWIRE) -- 12/15/2017 -- In a new report titled 'Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025,' Persistence Market Research analyzes the global non-melanoma skin cancer ... […]
- Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-cancer Activity in Ocular Melanoma Tumors on December 14, 2017 at 8:28 am
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, today announced that researchers at Massachusetts Eye and ... […]
- Melanoma Education Foundation Appoints CEO on December 13, 2017 at 11:47 am
Dr. Leslie Brody has joined the non-profit Melanoma Education Foundation of Peabody as Chief Executive Officer. Most recently he was President and CEO of the Epilepsy Foundation of New England, a position he held for 13 years. Prior to then he was ... […]
- What is metastasized ocular melanoma? A look at Blanco's fight on December 12, 2017 at 9:37 pm
There are only about 2,500 cases of ocular melanoma each year, so experts say it's not surprising not a lot is known about the cancer. Like skin cancer, the disease preys on melanoma cells in eye. Chances of it metastasizing, or spreading to other organs ... […]
- Opportunities on Melanoma Therapeutics Market on December 7, 2017 at 12:03 am
The elevated demand of innovative early stage and advanced melanoma treatments along with a thriving patient base, has generated an imminent need for improved therapies in the melanoma market. Even though, a plethora of treatment choices are accessible ... […]
- Looking Below The Locks: Teaching Hairdressers To Spot Melanoma on December 6, 2017 at 1:09 pm
Of all types of skin cancer, melanoma causes the majority of deaths. When on the scalp it can be especially difficult to catch in a self-examination — when was the last time you examined the top of your head? One person who might be able to help: your ... […]
- Melanoma Drugs Industry: 2017 Global Market Size, Share, Growth, Trends, 10 Key Companies Profile, Competitive Assessment and Demand Forecast To 2023 on December 5, 2017 at 6:06 am
The Global Melanoma Drugs Market is expected to be growing with a CAGR of XX% till 2023. This report offers comprehensive coverage on global market along with, market trends, drivers, and restraints of the market. This report included a detailed ... […]
- Role of melanoma-promoting protein revealed on December 5, 2017 at 12:00 am
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer. The gene, MELK, encodes a protein kinase — an enzyme that modifies other proteins — and is over-expressed in melanoma ... […]
- Craig Ceol lab identifies protein associated with metastatic melanoma on December 4, 2017 at 11:31 pm
A study by Craig J. Ceol, PhD, assistant professor of molecular medicine, has revealed that a protein called GDF6, active during early embryo development, plays a primary role in metastatic melanoma. Published in the Journal of Clinical Investigation by Dr ... […]
via Google News and Bing News